NASDAQ:MOR

MorphoSys Stock Forecast, Price & News

$29.86

-0.66 (-2.16 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$29.60

Now: $29.86▼

$30.45

50-Day Range

$27.39

MA: $28.35▼

$30.52

52-Week Range

$18.21

Now: $29.86▼

$35.73

Volume25,569 shs

Average Volume33,982 shs

Market Capitalization$3.93 billion

P/E Ratio142.20

Dividend YieldN/A

Beta1.03

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

MarketRank^™

Overall MarketRank^™

0.40 out of 5 stars

Medical Sector

1685th out of 1,926 stocks

Pharmaceutical Preparations Industry

702nd out of 773 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for MorphoSys.

2.0 Community Rank

Outperform Votes
MorphoSys has received 2 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MorphoSys has received 3 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MorphoSys has received 60.00% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote “Outperform” if you believe MOR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MorphoSys does not currently pay a dividend.
Dividend Growth
MorphoSys does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MorphoSys insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 3.06% of the stock of MorphoSys is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for MorphoSys are expected to decrease in the coming year, from $0.38 to ($0.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MorphoSys is 142.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.59.
Price to Earnings Ratio vs. Sector
The P/E ratio of MorphoSys is 142.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 35.82.
Price to Book Value per Share Ratio
MorphoSys has a P/B Ratio of 8.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MOR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.morphosys.com

Phone49 89 89927 0

Employees640

Debt

Debt-to-Equity RatioN/A

Current Ratio5.02

Quick Ratio4.93

Price-To-Earnings

Trailing P/E Ratio142.20

Forward P/E Ratio78.58

P/E GrowthN/A

Sales & Book Value

Annual Sales$80.43 million

Price / Sales48.84

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.49 per share

Price / Book8.56

Profitability

EPS (Most Recent Fiscal Year)($0.91)

Net Income$-115,380,000.00

Net Margins8.76%

Return on Equity4.51%

Return on Assets2.25%

Miscellaneous

Outstanding Shares131,560,000

Market Cap$3.93 billion

Next Earnings Date3/17/2021 (Estimated)

OptionableNot Optionable

$29.86

-0.66 (-2.16 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

MorphoSys (NASDAQ:MOR) Frequently Asked Questions

How has MorphoSys' stock been impacted by COVID-19 (Coronavirus)?

MorphoSys' stock was trading at $25.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MOR stock has increased by 18.2% and is now trading at $29.86.
View which stocks have been most impacted by COVID-19.

Is MorphoSys a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MorphoSys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View analyst ratings for MorphoSys or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than MorphoSys?

Wall Street analysts have given MorphoSys a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MorphoSys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as MorphoSys' CEO?

1,448 employees have rated MorphoSys CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among MorphoSys' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Wednesday, March 17th 2021.
View our earnings forecast for MorphoSys.

How were MorphoSys' earnings last quarter?

MorphoSys AG (NASDAQ:MOR) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.02. The business had revenue of $25.71 million for the quarter, compared to the consensus estimate of $22.23 million. MorphoSys had a net margin of 8.76% and a return on equity of 4.51%.
View MorphoSys' earnings history.

What guidance has MorphoSys issued on next quarter's earnings?

MorphoSys issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, November, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370.446-382.132 million, compared to the consensus revenue estimate of $428.92 million.

Who are some of MorphoSys' key competitors?

Some companies that are related to MorphoSys include Elanco Animal Health (ELAN), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE) and Sarepta Therapeutics (SRPT).
View all of MOR's competitors.

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:

Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 55)
Mr. Jens H. Holstein, CFO & Member of the Management Board (Age 57)
Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 58)
Mr. Roland Wandeler Ph.D., COO & Member of Management Board (Age 48)
Mr. Klaus De Wall, Head of Accounting & Tax
Ms. Lara Smith Weber, Head of Controlling, Corp. Fin. & Corp. Devel.
Dr. Margit Urban, Head of Discovery Alliances & Technologies
Dr. Julia Neugebauer Ph.D., Director of Investor Relations
Dr. Armin Weidmann, Head of Compliance and Quality Assurance
Ms. Charlotte Lohmann, Sr. VP & Gen. Counsel (Age 50)

When did MorphoSys IPO?

(MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

What is MorphoSys' stock symbol?

MorphoSys trades on the NASDAQ under the ticker symbol "MOR."

Who are MorphoSys' major shareholders?

MorphoSys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include OneAscent Financial Services LLC (0.01%).

Which major investors are buying MorphoSys stock?

MOR stock was purchased by a variety of institutional investors in the last quarter, including OneAscent Financial Services LLC.

How do I buy shares of MorphoSys?

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $29.86.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $3.93 billion and generates $80.43 million in revenue each year. The company earns $-115,380,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. MorphoSys employs 640 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.com.

How can I contact MorphoSys?

MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The company can be reached via phone at 49 89 89927 0 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here